Department of Medicine, Padua University Hospital, I-35128 Padua, Italy.
Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.
Int J Mol Sci. 2023 Aug 30;24(17):13432. doi: 10.3390/ijms241713432.
Hepatocellular carcinoma (HCC), the most common form of liver cancer, is frequently diagnosed late due to the absence of symptoms during early disease, thus heavily affecting the overall survival of these patients. Soluble immunological factors persistently produced during cirrhosis have been recognized as promoters of chronic inflammation and neoplastic transformation. The aim of this pilot study was to evaluate the predictive value of the cytokine profiles for HCC development. A Luminex xMAP approach was used for the quantification of 45 proteins in plasma and ascitic fluids of 44 cirrhotic patients without or with HCC of different etiologies. The association with patient survival was also evaluated. Univariate analyses revealed that very low levels of interleukin 5 (IL-5) (<15.86 pg/mL) in ascites and IL-15 (<12.40 pg/mL) in plasma were able to predict HCC onset with an accuracy of 81.8% and a sensitivity of 95.2%. Univariate analyses also showed that HCC, hepatitis B virus/hepatitis C virus infections, low levels of IL-5 and granulocyte-macrophage colony-stimulating factor in ascitic fluids, and high levels of eotaxin-1, hepatocyte growth factor and stromal-cell-derived factor 1α in plasma samples were factors potentially associated with a poor prognosis and decreased survival. Our results suggest a potential protective role of some immune modulators that may act in the peritoneal cavity to counteract disease progression leading to HCC development.
肝细胞癌(HCC)是最常见的肝癌形式,由于早期疾病无症状,常常诊断较晚,严重影响这些患者的总体生存率。肝硬化期间持续产生的可溶性免疫因子被认为是慢性炎症和肿瘤转化的促进因素。本初步研究旨在评估细胞因子谱对 HCC 发展的预测价值。我们使用 Luminex xMAP 方法定量检测 44 例无 HCC 和有不同病因 HCC 的肝硬化患者血浆和腹水的 45 种蛋白。还评估了与患者生存的关联。单因素分析显示,腹水和血浆中白细胞介素 5(IL-5)(<15.86 pg/mL)和白细胞介素 15(IL-15)(<12.40 pg/mL)极低水平能够以 81.8%的准确率和 95.2%的灵敏度预测 HCC 发病。单因素分析还表明,HCC、乙型肝炎病毒/丙型肝炎病毒感染、腹水低水平的 IL-5 和粒细胞-巨噬细胞集落刺激因子,以及血浆中高水平的嗜酸细胞趋化因子-1、肝细胞生长因子和基质细胞衍生因子 1α是与预后不良和生存时间缩短相关的潜在因素。我们的结果表明,一些免疫调节剂可能具有潜在的保护作用,它们可能在腹腔内发挥作用,以对抗导致 HCC 发展的疾病进展。